Oral administration of beta-cryptoxanthin prevents bone loss in streptozotocin-diabetic rats in vivo.
The effects of beta-cryptoxanthin, a carotenoid, on bone components in the femoral-diaphyseal and -metaphyseal tissues of streptozotocin (STZ)-diabetic rats was investigated. Rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and then the animal were orally administered beta-cryptoxanthin (5 or 10 microg/100 g body weight) once daily for 7 or 14 d. The administration of STZ caused a significant decrease in body weight and a significant increase in serum glucose, triglyceride, and calcium levels, indicating a diabetic state. These alterations were significantly prevented by the administration of beta-cryptoxanthin (5 or 10 microg/100 g) for 14 d. The administration of beta-cryptoxanthin (5 or 10 microg/100 g) to normal rats for 14 d did not have a significant effect on body weight or on serum glucose, triglyceride, and calcium levels. Calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues were significantly decreased in STZ-diabetic rats. These decreases were significantly prevented by the administration of beta-cryptoxanthin (5 or 10 microg/100 g) for 14 d. The administration of beta-cryptoxanthin to normal rats for 14 d caused a significant increase in calcium content, alkaline phosphatase activity, and DNA content in the femoral-diaphyseal and -metaphyseal tissues. This study demonstrates that the intake of beta-cryptoxanthin has a preventive effect on bone loss in STZ-diabetic rats.
Uchiyama
Satoshi
S
Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka, Japan.
Yamaguchi
Masayoshi
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control*; D002118:Calcium / Q000097:blood; D065366:Cryptoxanthins; D048909:Diabetes Complications / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D005269:Femur / Q000473:pathology; D008297:Male; D010710:Phosphates / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood; D024341:Xanthophylls; D019207:beta Carotene / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001786:Blood Glucose; D065366:Cryptoxanthins; D010710:Phosphates; D014280:Triglycerides; D024341:Xanthophylls; D019207:beta Carotene; D002118:Calcium